Samuel Bertin1, Yukari Aoki-Nonaka1,2, Jihyung Lee1, Petrus R de Jong1, Peter Kim1, Tiffany Han1, Timothy Yu1, Keith To1, Naoki Takahashi1,2, Brigid S Boland3,4, John T Chang3,4, Samuel B Ho3,5, Scott Herdman1, Maripat Corr1, Alessandra Franco6, Sonia Sharma7, Hui Dong3, Armen N Akopian8, Eyal Raz1. 1. Division of Rheumatology, Allergy & Immunology, Department of Medicine, University of California San Diego, La Jolla, California, USA. 2. Department of Oral Biological Science, Niigata University Graduate School of Medical and Dental Sciences, Chuo-ku, Niigata, Japan. 3. Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California, USA. 4. Inflammatory Bowel Disease Center, University of California San Diego, La Jolla, California, USA. 5. Division of Gastroenterology, Department of Medicine, VA San Diego Healthcare System, San Diego, California, USA. 6. Department of Pediatrics, University of California San Diego, La Jolla, California, USA. 7. La Jolla Institute for Allergy and Immunology, La Jolla, California, USA. 8. Department of Endodontics, UTHSCSA, San Antonio, Texas, USA.
Abstract
OBJECTIVE: Transient receptor potential ankyrin-1 (TRPA1) and transient receptor potential vanilloid-1 (TRPV1) are calcium (Ca2+)-permeable ion channels mostly known as pain receptors in sensory neurons. However, growing evidence suggests their crucial involvement in the pathogenesis of IBD. We explored the possible contribution of TRPA1 and TRPV1 to T-cell-mediated colitis. DESIGN: We evaluated the role of Trpa1 gene deletion in two models of experimental colitis (ie, interleukin-10 knockout and T-cell-adoptive transfer models). We performed electrophysiological and Ca2+ imaging studies to analyse TRPA1 and TRPV1 functions in CD4+ T cells. We used genetic and pharmacological approaches to evaluate TRPV1 contribution to the phenotype of Trpa1-/- CD4+ T cells. We also analysed TRPA1 and TRPV1 gene expression and TRPA1+TRPV1+ T cell infiltration in colonic biopsies from patients with IBD. RESULTS: We identified a protective role for TRPA1 in T-cell-mediated colitis. We demonstrated the functional expression of TRPA1 on the plasma membrane of CD4+ T cells and identified that Trpa1-/- CD4+ T cells have increased T-cell receptor-induced Ca2+ influx, activation profile and differentiation into Th1-effector cells. This phenotype was abrogated upon genetic deletion or pharmacological inhibition of the TRPV1 channel in mouse and human CD4+ T cells. Finally, we found differential regulation of TRPA1 and TRPV1 gene expression as well as increased infiltration of TRPA1+TRPV1+ T cells in the colon of patients with IBD. CONCLUSIONS: Our study indicates that TRPA1 inhibits TRPV1 channel activity in CD4+ T cells, and consequently restrains CD4+ T-cell activation and colitogenic responses. These findings may therefore have therapeutic implications for human IBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE:Transient receptor potential ankyrin-1 (TRPA1) and transient receptor potential vanilloid-1 (TRPV1) are calcium (Ca2+)-permeable ion channels mostly known as pain receptors in sensory neurons. However, growing evidence suggests their crucial involvement in the pathogenesis of IBD. We explored the possible contribution of TRPA1 and TRPV1 to T-cell-mediated colitis. DESIGN: We evaluated the role of Trpa1 gene deletion in two models of experimental colitis (ie, interleukin-10 knockout and T-cell-adoptive transfer models). We performed electrophysiological and Ca2+ imaging studies to analyse TRPA1 and TRPV1 functions in CD4+ T cells. We used genetic and pharmacological approaches to evaluate TRPV1 contribution to the phenotype of Trpa1-/- CD4+ T cells. We also analysed TRPA1 and TRPV1 gene expression and TRPA1+TRPV1+ T cell infiltration in colonic biopsies from patients with IBD. RESULTS: We identified a protective role for TRPA1 in T-cell-mediated colitis. We demonstrated the functional expression of TRPA1 on the plasma membrane of CD4+ T cells and identified that Trpa1-/- CD4+ T cells have increased T-cell receptor-induced Ca2+ influx, activation profile and differentiation into Th1-effector cells. This phenotype was abrogated upon genetic deletion or pharmacological inhibition of the TRPV1 channel in mouse and humanCD4+ T cells. Finally, we found differential regulation of TRPA1 and TRPV1 gene expression as well as increased infiltration of TRPA1+TRPV1+ T cells in the colon of patients with IBD. CONCLUSIONS: Our study indicates that TRPA1 inhibits TRPV1 channel activity in CD4+ T cells, and consequently restrains CD4+ T-cell activation and colitogenic responses. These findings may therefore have therapeutic implications for human IBD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Entities:
Keywords:
CALCIUM; EXPERIMENTAL COLITIS; IBD; ION CHANNELS; T LYMPHOCYTES
Authors: José M González-Navajas; Sean Fine; Jason Law; Sandip K Datta; Kim P Nguyen; Mandy Yu; Maripat Corr; Kyoko Katakura; Lars Eckman; Jongdae Lee; Eyal Raz Journal: J Clin Invest Date: 2010-01-04 Impact factor: 14.808
Authors: Alexander Schwarz; Eberhard Tutsch; Bianca Ludwig; Eva C Schwarz; Andreas Stallmach; Markus Hoth Journal: J Biol Chem Date: 2003-10-29 Impact factor: 5.157
Authors: S Bertin; B Lozano-Ruiz; V Bachiller; I García-Martínez; S Herdman; P Zapater; R Francés; J Such; J Lee; E Raz; J M González-Navajas Journal: Mucosal Immunol Date: 2014-09-17 Impact factor: 7.313
Authors: Ione Pereira; Saulo J F Mendes; Domingos M S Pereira; Thayanne F Muniz; Valderlane L P Colares; Cinara R A V Monteiro; Mahiba M R de S Martins; Marcos A G Grisotto; Valério Monteiro-Neto; Sílvio G Monteiro; João B Calixto; Susan D Brain; Elizabeth S Fernandes Journal: Front Pharmacol Date: 2017-02-10 Impact factor: 5.810
Authors: Mohammad Khalil; Korina Alliger; Carl Weidinger; Cansu Yerinde; Stefan Wirtz; Christoph Becker; Matthias Agop Engel Journal: Front Immunol Date: 2018-02-07 Impact factor: 7.561